Artificial liver plasma adsorption improves survival in elderly patients with severe pneumonia: a retrospective cohort study
Abstract
Objective To assess the therapeutic efficacy of artificial liver plasma adsorption (ALPA) in patients with severe pneumonia. Methods This retrospective study enrolled 151 patients meeting severe pneumonia diagnostic criteria who were admitted to the intensive care unit at Shulan Hospital, Hangzhou, China, between January 2020 and December 2024. Participants were allocated to either: (1) the ALPA intervention group (n = 56) receiving artificial liver plasma adsorption (ALPA) therapy, or (2) the control group (n = 95) receiving standard treatment. This study prospectively collected comprehensive clinical data, including: (1) baseline demographic characteristics; (2) serial measurements of laboratory parameters (e.g., white blood cell count (WBC), lymphocyte percentage (LY%), C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6)) at pre- and post-treatment intervals; and (3) Pneumonia Severity Index (PSI) scores at admission. Patient survival outcomes were systematically recorded, including: (1) time-to-event endpoints (overall survival duration from enrollment to death or last follow-up), and (2) clinical outcomes. Results No statistically significant differences were observed between the two groups regarding WBC, CRP, PCT, or IL-6 levels at baseline (all p ≥ 0.05). However, the LY% in the artificial liver treatment group was significantly lower compared to the conventional therapy group (p < 0.05). Post-treatment analysis revealed that the ALPA group…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 151 participants or records.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.